The use of interim PET/CT imaging has limited prognostic value to patients with diffuse large B-cell lymphoma (DLBCL) being treated with R-CHOP-14 (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days), the results of a large trial have indicated. {read more here}